Pharmacokinetics interaction studies between rifampicin and protease inhibitors: Methodological problems
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2008
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 05312caa a22008297a 4500 | ||
|---|---|---|---|
| 001 | PAPER-22299 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230607132520.0 | ||
| 008 | 190411s2008 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-53549115340 | |
| 024 | 7 | |2 cas |a aminotransferase, 9031-66-7; cytochrome P450 3A4, 329736-03-0; proteinase inhibitor, 37205-61-1; rifampicin, 13292-46-1; ritonavir, 155213-67-5; saquinavir, 127779-20-8, 149845-06-7; Antibiotics, Antitubercular; HIV Protease Inhibitors; Rifampin, 13292-46-1 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a AIDSE | ||
| 100 | 1 | |a Toibaro, J.J. | |
| 245 | 1 | 0 | |a Pharmacokinetics interaction studies between rifampicin and protease inhibitors: Methodological problems |
| 260 | |c 2008 | ||
| 270 | 1 | 0 | |m Toibaro, J. J.; Hospital General de Agudos José Maria Ramos Mejía, Urquiza 609, Pabellón de Clínica, 20 Piso, C1221 ADC Buenos Aires, Argentina; email: jtoibaro@hivramos.org.ar |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Maher, D., Floyd, K., Raviglione, M., (2002) A strategic framework to decrease the burden of TB/HIV, , Geneva, Switzerland: World Health Organization;, WHO/CDSATB/2002.296 | ||
| 504 | |a Piscitelli, S.C., Gallicano, K.D., Interactions among drugs for HIV and opportunistic infections (2001) N Engl J Med, 344, pp. 984-996 | ||
| 504 | |a Dean, G.L., Edwards, S.G., Ives, N.J., Matthews, G., Fox, E.F., Navaratne, L., Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy (2002) AIDS, 16, pp. 75-83 | ||
| 504 | |a Dear Healthcare Provider letter. Roche Pharmaceuticals; 7 February 2005. http://www.fda.gov/medwatch/SAFETY/2005/safe-ty05.htm#lnvirase. [Accessed 11 February 2005]; Nijland, H.M.J., L'homme, R.F.A., Rongen, G.A., van Uden, P., van Crevel, R., Boeree, M.J., High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets (2008) AIDS, 22, pp. 931-935 | ||
| 504 | |a la Porte, C.J.L., Colbers, E.P.H., Bertz, R., Voncken, D.S., Wikstrom, K., Boeree, M.J., Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers (2004) Antimicrob Agents Chemother, 48, pp. 1553-1560 | ||
| 504 | |a Ribera, E., Azuaje, C., Lopez, R.M., Domingo, P., Curran, A., Feijoo, M., Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis (2007) J Antimicrob Chemother, 59, pp. 690-697 | ||
| 504 | |a Gurumurthy, P., Ramachandran, G., Hemanth Kumar, A.K., Rajasekaran, S., Padmapriyadarsini, C., Swaminathan, S., Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease (2004) Antimicrob Agents Chemother, 48, pp. 4473-4475 | ||
| 504 | |a Losso, M.H., Lourtau, L.D., Toibaro, J.J., Saenz, C., Gonzalez, C., The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin (2004) Antivir Ther, 9, pp. 1031-1033 | ||
| 593 | |a Hospital José María Ramos Mejía, Pabellón de Clínica, Buenos Aires, Argentina | ||
| 593 | |a Hospital General de Agudos José Maria Ramos Mejía, Urquiza 609, Pabellón de Clínica, 20 Piso, C1221 ADC Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a AMINOTRANSFERASE |
| 690 | 1 | 0 | |a CYTOCHROME P450 3A4 |
| 690 | 1 | 0 | |a GLYCOPROTEIN P |
| 690 | 1 | 0 | |a LOPINAVIR PLUS RITONAVIR |
| 690 | 1 | 0 | |a PROTEINASE INHIBITOR |
| 690 | 1 | 0 | |a RIFAMPICIN |
| 690 | 1 | 0 | |a RITONAVIR |
| 690 | 1 | 0 | |a RITONAVIR PLUS SAQUINAVIR |
| 690 | 1 | 0 | |a SAQUINAVIR |
| 690 | 1 | 0 | |a UNCLASSIFIED DRUG |
| 690 | 1 | 0 | |a AMINOTRANSFERASE BLOOD LEVEL |
| 690 | 1 | 0 | |a CLINICAL TRIAL |
| 690 | 1 | 0 | |a DRUG ABSORPTION |
| 690 | 1 | 0 | |a DRUG EXCRETION |
| 690 | 1 | 0 | |a DRUG METABOLISM |
| 690 | 1 | 0 | |a HIGHLY ACTIVE ANTIRETROVIRAL THERAPY |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a HUMAN IMMUNODEFICIENCY VIRUS INFECTION |
| 690 | 1 | 0 | |a LETTER |
| 690 | 1 | 0 | |a LIVER TOXICITY |
| 690 | 1 | 0 | |a MIXED INFECTION |
| 690 | 1 | 0 | |a PATIENT COMPLIANCE |
| 690 | 1 | 0 | |a PHARMACOKINETICS |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a SIDE EFFECT |
| 690 | 1 | 0 | |a AIDS-RELATED OPPORTUNISTIC INFECTIONS |
| 690 | 1 | 0 | |a ANTIBIOTICS, ANTITUBERCULAR |
| 690 | 1 | 0 | |a DRUG INTERACTIONS |
| 690 | 1 | 0 | |a HIV PROTEASE INHIBITORS |
| 690 | 1 | 0 | |a HUMANS |
| 690 | 1 | 0 | |a LIVER DISEASES |
| 690 | 1 | 0 | |a RESEARCH DESIGN |
| 690 | 1 | 0 | |a RIFAMPIN |
| 650 | 1 | 7 | |2 spines |a TUBERCULOSIS |
| 650 | 1 | 7 | |2 spines |a TUBERCULOSIS |
| 700 | 1 | |a Losso, M.H. | |
| 773 | 0 | |d 2008 |g v. 22 |h pp. 2046-2047 |k n. 15 |p AIDS |x 02699370 |t AIDS | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-53549115340&doi=10.1097%2fQAD.0b013e3283112bb7&partnerID=40&md5=9e728299ba7cdd20e6a11547f8894e2d |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1097/QAD.0b013e3283112bb7 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_02699370_v22_n15_p2046_Toibaro |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_02699370_v22_n15_p2046_Toibaro |y Registro en la Biblioteca Digital |
| 961 | |a paper_02699370_v22_n15_p2046_Toibaro |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 83252 | ||